Veralto Corporation $VLTO Position Trimmed by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. cut its holdings in Veralto Corporation by 71%, now owning 468,331 shares worth approximately $45.64 million.
• Veralto reported earnings per share (EPS) of $0.93 for the last quarter, exceeding analyst expectations, with revenues totaling $1.37 billion.
• Analysts have shown strong support for Veralto, with several upgrading the stock to a "strong-buy" rating and an average price target of $113.43.

Jacobs Levy Equity Management Inc. lessened its stake in shares of Veralto Corporation (NYSE:VLTO - Free Report) by 71.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 468,331 shares of the company's stock after selling 1,144,495 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.19% of Veralto worth $45,639,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Gotham Asset Management LLC increased its position in Veralto by 26.7% during the 1st quarter. Gotham Asset Management LLC now owns 187,533 shares of the company's stock worth $18,275,000 after purchasing an additional 39,540 shares in the last quarter. Hall Laurie J Trustee increased its position in Veralto by 6.0% during the 1st quarter. Hall Laurie J Trustee now owns 20,082 shares of the company's stock worth $1,957,000 after purchasing an additional 1,133 shares in the last quarter. Alliancebernstein L.P. increased its position in Veralto by 28.0% during the 1st quarter. Alliancebernstein L.P. now owns 6,235,563 shares of the company's stock worth $607,656,000 after purchasing an additional 1,363,502 shares in the last quarter. AQR Capital Management LLC increased its position in Veralto by 133.2% during the 1st quarter. AQR Capital Management LLC now owns 455,220 shares of the company's stock worth $43,842,000 after purchasing an additional 260,002 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Veralto by 545.9% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 200,667 shares of the company's stock worth $19,555,000 after buying an additional 169,600 shares during the last quarter. Hedge funds and other institutional investors own 91.28% of the company's stock.

Insider Activity

In other Veralto news, CEO Jennifer Honeycutt sold 10,646 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $106.26, for a total value of $1,131,243.96. Following the transaction, the chief executive officer directly owned 106,219 shares of the company's stock, valued at $11,286,830.94. This represents a 9.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

VLTO has been the topic of several research analyst reports. Robert W. Baird raised their target price on shares of Veralto from $106.00 to $112.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 30th. Wolfe Research raised shares of Veralto from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, July 30th. Raymond James Financial initiated coverage on Veralto in a research note on Tuesday, August 26th. They issued a "market perform" rating on the stock. Stifel Nicolaus set a $120.00 price objective on Veralto and gave the company a "buy" rating in a research note on Wednesday, July 30th. Finally, Royal Bank Of Canada lifted their price objective on Veralto from $104.00 to $108.00 and gave the company a "sector perform" rating in a research note on Wednesday, July 30th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $113.43.

Veralto Stock Up 2.6%

Shares of NYSE VLTO traded up $2.71 during trading on Thursday, reaching $108.72. 343,339 shares of the stock were exchanged, compared to its average volume of 1,328,957. The business's 50-day moving average price is $105.30 and its 200 day moving average price is $99.82. Veralto Corporation has a twelve month low of $83.86 and a twelve month high of $115.00. The company has a quick ratio of 2.06, a current ratio of 2.32 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $26.98 billion, a price-to-earnings ratio of 30.37, a price-to-earnings-growth ratio of 3.49 and a beta of 0.91.

Veralto (NYSE:VLTO - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported $0.93 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.04. Veralto had a net margin of 16.65% and a return on equity of 41.45%. The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.34 billion. During the same period in the previous year, the company posted $0.85 earnings per share. The business's revenue for the quarter was up 6.4% compared to the same quarter last year. Veralto has set its FY 2025 guidance at 3.720-3.800 EPS. Q3 2025 guidance at 0.910-0.950 EPS. As a group, equities analysts forecast that Veralto Corporation will post 3.66 EPS for the current fiscal year.

Veralto Company Profile

Veralto Corporation provides water analytics, water treatment, marking and coding, and packaging and color services worldwide. It operates through two segments, Water Quality (WQ) and Product Quality & Innovation (PQI). The WQ segment offers precision instrumentation and water treatment technologies to measure, analyze, and treat water in residential, commercial, municipal, industrial, research, and natural resource applications through the Hach, Trojan Technologies, and ChemTreat brands.